← Back to headlines
Immunic Appoints Erik Lundgren as CEO to Advance Phase 3 MS Trials
Immunic has announced the appointment of Erik Lundgren, a former Genentech executive, as its new Chief Executive Officer, tasked with advancing the company's Phase 3 MS trials.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
BOJ Deputy Governor Urges Timely Interest Rate Hike Amid Inflation Pressures
23m ago
Asian Markets Show Mixed Gains as Nvidia Outlook Offsets Inflation Concerns
30m ago
Belgrade Prepares Tender for 85 New Trams Amid Early Concerns
37m ago
Energy Sector Firms Report Strong Financial Performance for Early 2026
41m ago